Published in Drug Law Weekly, October 13th, 2009
"These compounds were screened for antifungal activity in vitro against pathogenic fungi, namely, Sclerotium rolfsii and Rhizoctonia bataticola, and for their effect on nitrification inhibition under laboratory conditions. Maximum antifungal activity was exhibited by (2,4-dichloroben ylidene)-(2,4,5-trichlorophenyl)-amine and (3-nitrobenzylidene)-(2,4,5-trichlorophenyl)-amine against both fungi (ED50 with range from 3 to 24 mu g/mL)," wrote N. Aggarwal and colleagues.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.